［1］Chen Y, Si JM, Liu WL, Cai JT, Du Q, Wang LJ, et al. Induction of experimental acute ulcerative colitis in rats by administration of dextran sulfate sodium at low concentration followed by intracolonic administration of 30% ethanol［J］. J Zhejiang Univ Sci B, 2007, 8(9): 632-637.

［2］Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function［J］. Ann N Y Acad Sci, 2009, 1165: 183-189.

［3］Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice［J］. Gastroenterology, 1990, 98(3): 694-702.

［4］Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis［J］. Lab Invest, 1993, 69(2): 238-249.

［5］Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk［J］. Gastroenterology, 2000, 119(6): 1740-1744.

［6］Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Sch-lmerich J, et al. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats［J］. Int J Colorectal Dis, 2001, 16(4): 238-246.

 ［7］Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, et al. The dextran sulphate sodium (DSS) model of colitis: an overview［J］. Comp Clin Pathol, 2010, 19(3): 235-239.

 ［8］Whittem CG, Williams AD, Williams CS. Murine Colitis modeling using Dextran Sulfate Sodium (DSS)［J］. J Vis Exp, 2010, 35: 6-8.

 ［9］Sutton SC, Forbes AE, Cargill R, Hochman JH, LeCluyse EL. Simultaneous in vitro measurement of intestinal tissue permeability and transepithelial electrical resistance (TEER) using Sweetana-Grass diffusion cells［J］. Pharm Res, 1992, 9(3): 316-319.

［10］Ewe K. Intestinal transport in constipation and diarrhoea［J］. Pharmacology, 1988, 36(Suppl 1): 73-84.

［11］Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes［J］. J Appl Toxicol, 2001, 21(1): 15-23.

［12］Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment［J］. Gut, 2004, 53(9): 1295-1302.

［13］Shimizu T, Kitamura T, Suzuki M, Fujii T, Shoji H, Tanaka K, et al. Effects of alpha-linolenic acid on colonic secretion in rats with experimental colitis［J］. J Gastroenterol, 2007, 42(2): 129-134.

［14］Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex［J］. Ann N Y Acad Sci, 2006, 1072: 242-252.

［15］Lapierre LA. The molecular structure of the tight junction［J］. Adv Drug Deliv Rev, 2000, 41(3): 255-264.

［16］Madara JL. Regulation of the movement of solutes across tight junctions［J］. Annu Rev Physiol, 1998, 60: 143-159.

［17］Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein［J］. J Cell Biol, 1996, 134(4): 1031-1049.

［18］Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis［J］. J Gastroenterol Hepatol, 2008, 23(Suppl 2): S146-S150.

［19］Saitou M, Fujimoto K, Doi Y, Itoh M, Fujimoto T, Furuse M, et al. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions［J］. J Cell Biol, 1998, 141(2): 397-408.

［20］Turksen K, Troy TC. Barriers built on claudins［J］. J Cell Sci, 2004, 117(Pt 12): 2435-2447.

［21］Amasheh S, Fromm M, Günzel D. Claudins of intestine and nephron-a correlation of molecular tight junction structure and barrier function［J］. Acta Physiol (Oxf), 2011, 201(1): 133-140.

［22］Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells［J］. J Cell Sci, 2002, 115(Pt 24): 4969-4976.

［23］Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton［J］. J Biol Chem, 1998, 273(45): 29745-29753.

［24］Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease［J］. Gut, 2007, 56(1): 61-72.

 ［25］ Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis［J］. J Surg Res, 2007, 140(1): 12-19.

［26］Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression［J］. Am J Pathol, 2005, 166(2): 409-419.

［27］Feighery LM, Cochrane SW, Quinn T, Baird AW, O'Toole D, Owens SE, et al. Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro［J］. Pharm Res, 2008, 25(6): 1377-1386.

［28］Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown［J］. Curr Opin Pharmacol, 2009, 9(6): 715-720.